If you find yourself with $1,000 all of a sudden — or perhaps through slow consistent saving — you might be wondering: What’s next? Maybe ideas of a beach vacation are floating through your head, or maybe you’re thinking about buying yourself a big-ticket gadget like a new computer or TV.
You can certainly spend your money on those things if you want, but here are 10 smart things you could do with that $1,000 right now to improve your financial well-being.
Image source: Getty Images.
1. Pay off your debts
If you’re carrying any high-interest debt like a balance on your credit card, medical bills, or a personal line of credit, you should absolutely be paying it off as quickly as possible. $1,000 can go a long way toward clearing your debt, especially if you’re only making minimum monthly payments.
When you pay off high-interest debt, you’re effectively getting a guaranteed return on investment for your $1,000. So, if you have $1,000 in credit card debt accruing interest at a 20% annual rate, you’ll save $200 per year in interest expenses you would have paid if you didn’t pay down that debt.
Hot Medical Stocks To Invest In Right Now: John B. Sanfilippo & Son, Inc.(JBSS)
Advisors’ Opinion:
- [By Max Byerly]
John B. Sanfilippo & Son, Inc. (NASDAQ:JBSS) shares reached a new 52-week high and low during trading on Wednesday . The stock traded as low as $71.43 and last traded at $70.96, with a volume of 1305 shares trading hands. The stock had previously closed at $69.72.
- [By Max Byerly]
The Hershey (NYSE: HSY) and John B. Sanfilippo & Son (NASDAQ:JBSS) are both consumer staples companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.
- [By Joseph Griffin]
BidaskClub upgraded shares of John B. Sanfilippo & Son (NASDAQ:JBSS) from a hold rating to a buy rating in a research note released on Wednesday.
Hot Medical Stocks To Invest In Right Now: BioScrip, Inc.(BIOS)
Advisors’ Opinion:
- [By Money Morning News Team]
BioScrip Inc.(Nasdaq: BIOS) provides at-home medical care and services across the United States.
BIOS’s central profit opportunity is in the rapid growth of the pharmaceutical industry. The pharmaceutical market is currently worth $12 billion and is expected to grow at an annual rate of five to seven percent.
- [By Logan Wallace]
BioScrip (NASDAQ: BIOS) and Chemed (NYSE:CHE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on BioScrip (BIOS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
Get a free copy of the Zacks research report on BioScrip (BIOS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Shane Hupp]
BiosCrypto (CURRENCY:BIOS) traded flat against the US dollar during the 24 hour period ending at 22:00 PM E.T. on June 14th. BiosCrypto has a total market cap of $26,890.00 and $0.00 worth of BiosCrypto was traded on exchanges in the last day. One BiosCrypto coin can now be bought for approximately $0.0013 or 0.00000017 BTC on major exchanges. In the last week, BiosCrypto has traded down 13.4% against the US dollar.
- [By Shane Hupp]
BioScrip (NASDAQ: BIOS) and Amedisys Home Health and Hospice Care (NASDAQ:AMED) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, earnings, dividends and risk.
Hot Medical Stocks To Invest In Right Now: SuperValu Inc.(SVU)
Advisors’ Opinion:
- [By Lisa Levin] Companies Reporting Before The Bell
United Technologies Corporation (NYSE: UTX) is estimated to report quarterly earnings at $1.51 per share on revenue of $14.62 billion.
The Coca-Cola Company (NYSE: KO) is expected to report quarterly earnings at $0.46 per share on revenue of $7.31 billion.
Caterpillar Inc. (NYSE: CAT) is projected to report quarterly earnings at $2.07 per share on revenue of $11.93 billion.
Verizon Communications Inc. (NYSE: VZ) is expected to report quarterly earnings at $1.11 per share on revenue of $31.22 billion.
Lockheed Martin Corporation (NYSE: LMT) is estimated to report quarterly earnings at $3.42 per share on revenue of $11.28 billion.
The Sherwin-Williams Company (NYSE: SHW) is projected to report quarterly earnings at $3.15 per share on revenue of $3.94 billion.
Biogen Inc. (NASDAQ: BIIB) is expected to report quarterly earnings at $5.92 per share on revenue of $3.15 billion.
3M Company (NYSE: MMM) is estimated to report quarterly earnings at $2.52 per share on revenue of $8.26 billion.
JetBlue Airways Corporation (NASDAQ: JBLU) is projected to report quarterly earnings at $0.2 per share on revenue of $1.75 billion.
Eli Lilly and Company (NYSE: LLY) is expected to report quarterly earnings at $1.13 per share on revenue of $5.49 billion.
Harley-Davidson, Inc. (NYSE: HOG) is estimated to report quarterly earnings at $0.88 per share on revenue of $1.25 billion.
Corning Incorporated (NYSE: GLW) is expected to report quarterly earnings at $0.3 per share on revenue of $2.50 billion.
Centene Corporation (NYSE: CNC) is projected to report quarterly earnings at $1.88 per share on revenue of $13.28 billion.
The Travelers Companies, Inc. (NYSE: TRV) is estimated to report quarterly earnings at $2.77 per share on revenue of $6.75 billion.
Wipro Limited (NYSE: WIT) is expected to report quarterly earnings at $0.07 per share on revenue of $2.16 billion.
PACCAR Inc (NASDAQ: PCAR) is projected to - [By Stephan Byrd]
SuperValu (NYSE:SVU) – Northcoast Research issued their Q1 2019 earnings per share estimates for SuperValu in a note issued to investors on Wednesday, May 9th. Northcoast Research analyst C. Cerankosky expects that the company will earn $0.65 per share for the quarter. Northcoast Research also issued estimates for SuperValu’s Q2 2019 earnings at $0.55 EPS, Q3 2019 earnings at $0.30 EPS, Q4 2019 earnings at $0.54 EPS and FY2019 earnings at $2.04 EPS.
- [By Brian Stoffel]
But over the past five years, the industry has been turned upside down by changes in business models, a focus on delivery, and mass consolidation. While the dust is far from settled, here are 10 of the largest publicly traded grocers you can buy stock in.
Company Market Cap Stores Regions Chains
Amazon (NASDAQ:AMZN) $780 billion 500 USA Whole Foods
Walmart (NYSE:WMT) $250 billion 11,700 Worldwide Walmart
Costco (NASDAQ:COST) $86 billion 750 USA Costco
Kroger (NYSE:KR) $21 billion 2,800 USA Kroger, Roundy’s, Ralph’s, Food 4 Less
Sprouts (NASDAQ: SFM) $3 billion 300 Western and Southern U.S. Sprouts Farmer’s Market
Weis Market (NYSE: WMK) $1.3 billion 200 Mid-Atlantic U.S. Weis Market
SUPERVALU(NYSE: SVU) $630 million 100 Midwestern U.S. Cub Foods, Shopper’s Food, Hornbacher
Ingles Market(NASDAQ: IMKTA) $580 million 200 Southeastern U.S. Ingles Market, Sav-Mor
Smart & Final(NYSE: SFS) $360 million 350 Western U.S. Smart & Final, Cash & Carry
Natural Grocers (NYSE: NGVC) $230 million 150 Western U.S. Natural GrocersData source: Yahoo! Finance, company websites.
- [By Lisa Levin]
Wednesday morning, the consumer staples shares fell by just 0.2 percent. Meanwhile, top gainers in the sector included SUPERVALU Inc. (NYSE: SVU), up 4 percent, and Imperial Brands PLC (OTC: IMBBY), up 2 percent.
- [By Ethan Ryder]
TheStreet upgraded shares of SuperValu (NYSE:SVU) from a d+ rating to a c- rating in a report released on Tuesday.
Other equities research analysts also recently issued research reports about the company. Pivotal Research reissued a buy rating and issued a $24.00 price objective on shares of SuperValu in a report on Monday, April 23rd. ValuEngine downgraded SuperValu from a hold rating to a sell rating in a report on Wednesday, April 18th. Zacks Investment Research downgraded SuperValu from a buy rating to a hold rating in a report on Friday, April 27th. Morgan Stanley cut their price objective on SuperValu from $17.00 to $15.50 and set an equal weight rating for the company in a report on Thursday, April 26th. Finally, Credit Suisse Group began coverage on SuperValu in a report on Tuesday, April 17th. They issued an underperform rating and a $15.00 price objective for the company. Four investment analysts have rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company’s stock. SuperValu currently has a consensus rating of Hold and an average target price of $20.39.
Hot Medical Stocks To Invest In Right Now: Neuralstem, Inc.(CUR)
Advisors’ Opinion:
- [By Logan Wallace]
Shares of Neuralstem, Inc. (NASDAQ:CUR) were down 16% during mid-day trading on Friday . The stock traded as low as $1.24 and last traded at $1.37. Approximately 595,500 shares were traded during mid-day trading, an increase of 205% from the average daily volume of 195,111 shares. The stock had previously closed at $1.63.